BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 28, 2024
See today's BioWorld
Home
» Eylea blinks and Novartis looks to face-off in nAMD with brolucizumab
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Eylea blinks and Novartis looks to face-off in nAMD with brolucizumab
June 21, 2017
By
Marie Powers
No Comments
Novartis AG put its VEGF-A ligand inhibitor, brolucizumab (RTH-258), to the test in neovascular age-related macular degeneration (nAMD) against Regeneron Pharmaceuticals Inc.'s cash cow, Eylea (aflibercept), and appeared to come up a winner.
BioWorld